Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis

Checkpoint blocking therapies are used to treat metastatic melanoma, but can have adverse immune-mediated effects, including liver pathology. Here the authors identify an expanded pool of CD4+ effector memory T cells resulting from prior CMV exposure as a risk factor for this adverse effect in these...

Full description

Bibliographic Details
Main Authors: James A. Hutchinson, Katharina Kronenberg, Paloma Riquelme, Jürgen J. Wenzel, Gunther Glehr, Hannah-Lou Schilling, Florian Zeman, Katja Evert, Martin Schmiedel, Marion Mickler, Konstantin Drexler, Florian Bitterer, Laura Cordero, Lukas Beyer, Christian Bach, Josef Koestler, Ralph Burkhardt, Hans J. Schlitt, Dirk Hellwig, Jens M. Werner, Rainer Spang, Barbara Schmidt, Edward K. Geissler, Sebastian Haferkamp
Format: Article
Language:English
Published: Nature Portfolio 2021-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-21572-y
Description
Summary:Checkpoint blocking therapies are used to treat metastatic melanoma, but can have adverse immune-mediated effects, including liver pathology. Here the authors identify an expanded pool of CD4+ effector memory T cells resulting from prior CMV exposure as a risk factor for this adverse effect in these patients.
ISSN:2041-1723